- Evotec (OTCPK:EVOTF) forms a spin-off company, Topas Therapeutics GmbH, that will develop nanoparticle-based therapeutics focused on autoimmune diseases. Topas emerged from the neuro portfolio of Bionamics GmbH which Evotec acquired in March 2014. Its proprietary technology induces antigen-specific immune tolerance in the liver. Its initial program will be multiple sclerosis, with clinical development commencing in 2017.